Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
Sponsor: Janssen Research & Development, LLC
ClinicalTrials ID:NCT05463939
This expanded access protocol provides teclistamab SC to patients with relapsed or refractory multiple myeloma who have exhausted all standard treatments and are ineligible for clinical trials. Eligibility requires a diagnosis of relapsed or refractory multiple myeloma and the exhaustion of all approved treatment options.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.
Eligibility Criteria
Inclusion Criteria
- Patient diagnosed with Relapsed or Refractory Multiple Myeloma
- Patient exhausted all commercially approved and clinically appropriate (not patient or physician preference) treatment options, and is ineligible for a clinical trial
Get This Program In Your Inbox
You can sign up and apply your patients for this program.